CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.05
+2.61%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$8.91
From 52W high−34.18%
Volume972134.00
Market cap$692.49M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$8.91
From 52W high
−34.18%
Volume
972134.00
Market cap
$692.49M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.5x
P/E (TTM)
—
RSI (14)
45.7
MomentumView details →
1D Return
+2.61%
YTD Return
+55.75%
SummaryUpdated Jun 1, 2026
Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Needham, Massachusetts. Originally incorporated as Advantagene, Inc., the company rebranded to Candel Therapeutics in November 2020 before going public in July 2021. The company focuses on developing innovative immunotherapies designed to treat various forms of cancer by harnessing the body's immune system to fight tumors.
Similar companies
Latest newsMore news →
Candel Therapeutics presented new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in patients with localized intermediate- to high-risk prostate cancer at the ASTRO Annual Meeting 2026.35d agoCandel Therapeutics shares rose 7.56% to $11.67 after an analyst upgraded the stock to Buy and raised the price target to $18 from $12.44d ago